FibroBiologics, Inc.
New Form D on file · 2026-09-16 · the record
What the record says
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 111 filings in Pharmaceuticals, totalled by week. The dot is this raise, $500K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Use of proceeds, as written on the filing
The issuer intends to use the net proceeds from this offering for working capital and general corporate purposes.
Checked away from the filing. What is below does not come from the record on sec.gov.
FibroBiologics is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and…
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Company officers on record
On the filing as: Executive Officer, Director.
Pete O'Heeron is named as Chief Executive Officer on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
Richard Cilento is named as Director on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
Robert Hoffman is named as Director on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
Victoria Niklas is named as Director on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
Kathleen Rubins is named as Director on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
Leigh Steinberg is named as Director on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Jason Davis is named as Chief Financial Officer on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Ruben Garcia is named as General Counsel on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Hamid Khoja is named as Chief Scientific Officer on the Form D that FibroBiologics, Inc. filed with the SEC on 16 September 2026, one of 9 people that filing names.
9 people named on the filing — 4 holding an executive role and 5 as directors only.
Named as of the 2026-09-16 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
- 9 people named on the filing — 4 holding an executive role and 5 as directors only.
No investor is drawn from a Form D — the form states how many invested and never who.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on FibroBiologics, Inc.
- Source Check — verify Ruben A. Garcia's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Ruben A. Garcia for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist FibroBiologics, Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind FibroBiologics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-25 (ir.fibrobiologics.com).